CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

ConferenceFIT-001Darlifarnibdarlifarnib
Related Companies

Read the original article

Published by GlobeNewswire Pharma on July 14, 2026 11:02 AM

Read Original